论文部分内容阅读
目的:研究p33ING1在非小细胞肺癌(NSCLC)中的表达及其与临床病理特征的关系;探讨p33ING1在NSCLC发生、发展中的可能作用机制。方法:用免疫组化SP法检测p33ING1在40例NSCLC和10例正常肺组织中的表达。结果:p33ING1在NSCLC组织中阳性率(57.5%,23/40)低于正常肺组织(100.0%,10/10),两组有显著性差异(P<0.05)。p33ING1低表达与肺癌的分化程度、TNM分期及淋巴结转移均有关:p33ING1在无淋巴结转移组及淋巴结转移组癌组织中的阳性表达率分别为76.2%(16/21)、36.8%(7/19),两组有显著性差异(P<0.05);在UICC的TNM分期~期、~期组病例中分别为69.0%(20/29)、27.3%(3/11)(P<0.05);在高、中、低分化组病例中分别为87.5%(7/8)、66.7%(12/18)和14.3%(2/14),其中高、低分化组间及中、低分化组间的阳性表达率均具有极显著差异(P<0.01)。p33ING1的表达与其他临床病理参数(患者性别、年龄、病理组织学类型等)不相关(P>0.05)。结论:p33ING1在NSCLC中低表达,它的低表达对判断NSCLC恶性程度、浸润甚至转移有重要价值。p33ING1蛋白的低表达在NSCLC的发生发展中可能起重要作用。
Objective: To investigate the expression of p33ING1 in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features and to explore the possible mechanism of p33ING1 in the development and progression of NSCLC. Methods: The expression of p33ING1 in 40 cases of NSCLC and 10 cases of normal lung tissue was detected by immunohistochemical SP method. Results: The positive rate of p33ING1 in NSCLC tissues was lower than that in normal lung tissues (57.5%, 23/40%) (100.0%, 10/10). There was a significant difference between the two groups (P <0.05). The low expression of p33ING1 was correlated with the differentiation of lung cancer, TNM stage and lymph node metastasis. The positive expression rates of p33ING1 in non-lymph node metastasis and lymph node metastasis were 76.2% (16/21) and 36.8% (7/19) respectively ), There was significant difference between the two groups (P <0.05). In the stage of UICC TNM staging, they were 69.0% (20/29) and 27.3% (3/11) respectively (P <0.05) (87.5% (7/8), 66.7% (12/18) and 14.3% (2/14) respectively) in high, moderate and poorly differentiated group, (P <0.01). The expression of p33ING1 was not associated with other clinicopathological parameters (patient’s gender, age, histopathological type, etc.) (P> 0.05). Conclusion: p33ING1 is low expressed in NSCLC, and its low expression is of great value in judging the malignancy, invasion and metastasis of NSCLC. The low expression of p33ING1 protein may play an important role in the development of NSCLC.